04Jun/13

Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell … – MarketWatch

Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell
MarketWatch
Study Evaluating REVLIMID(R) Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at ASCO. MEL200 demonstrated a longer median PFS and OS compared
MEL200 demonstrated a longer median PFS and OS compared to MPR in the Investor’s Business Daily
ASCO 2012 Multiple Myeloma Update – Day Three: Poster PresentationsThe Myeloma Beacon

all 9 news articles »